Sarcopenia

IF 3 2区 医学 Q2 ENDOCRINOLOGY & METABOLISM Journal of Diabetes Pub Date : 2024-10-29 DOI:10.1111/1753-0407.70025
Zachary Bloomgarden
{"title":"Sarcopenia","authors":"Zachary Bloomgarden","doi":"10.1111/1753-0407.70025","DOIUrl":null,"url":null,"abstract":"<p>The term “sarcopenia” literally means “deficiency of flesh,” and is used to refer to lack of skeletal muscle. Numerous similar concepts in medicine describe the progressive loss, deficiency, atrophy, or wastage of muscle characteristic of many systemic illnesses and of aging itself. Depending on the definition used, sarcopenia affects large subsets of the population, in association with physical inactivity, cigarette smoking, and malnutrition but also paradoxically with obesity. Sarcopenia is seen with diabetes, pulmonary disease, heart disease, malignancy, and with psychiatric and neurologic illnesses including depression/anorexia and Alzheimer's and Parkinson's diseases.<span><sup>1</sup></span> In a study carried out nearly four decades ago, total appendicular skeletal muscle mass was found to decrease in a linear fashion with age both among men and women, regardless of race or ethnic group, showing positive correlation with body weight.<span><sup>2</sup></span> Sarcopenia can be assessed clinically with measures of strength such as the simple self-report of limitation of walking, which increases in prevalence with increasing age, to a greater extent in low- than in high-income countries, and which correlates strongly with all-cause mortality even after adjustment for age, sex, education, marital status, rural residence, and country income level, and additionally for hypertension, diabetes, coronary artery disease, stroke, body mass index (BMI), smoking, physical activity, and depression.<span><sup>3</sup></span> In a study analyzing mortality at &gt;12 year follow-up, those in the highest quintile of the fat-to-muscle mass ratio estimated using bioelectrical impedance among 337 951 UK Biobank participants had increased total and cardiovascular disease (CVD) mortality, both among men and women.<span><sup>4</sup></span></p><p>Clinical conditions associated with sarcopenia overlap with features of frailty such as slowing, falls, fatigue, and weight loss, which may represent disease prodromes,<span><sup>5</sup></span> with a continuum from robustness, with stressors leading to temporary decline in functional capacity, to pre-frailty, with only incomplete recovery from stressors, to actual frailty with failure to recover from stressors eventuating in states of dependence and disability.<span><sup>6</sup></span> The biology of frailty involves a number of factors associated with sarcopenia, including states of dysregulated nutrient sensing, such as abnormalities of mammalian target of rapamycin (mTOR) complex 1, AMP-activated protein kinase (AMPK), and the nutrient scarcity sensors sirtuins 1 and 3, and hormonal changes associated with aging including decreased levels of the anabolic hormones dehydroepiandrosterone sulfate, testosterone, growth hormone, and insulin-like growth factor 1, and increased levels of catabolic hormones, particularly cortisol.<span><sup>7</sup></span> Insulin can best be seen in this context as an anabolic hormone involved in nutrient storage, but rather than being deficient, it is typically present in excess in association with insulin resistance leading to reduction in its anabolic functional activity.<span><sup>8</sup></span></p><p>Sarcopenia is associated with chronic inflammation, mediated by cellular senescence and mitochondrial dysfunction, inhibiting growth factor expression, and causing DNA damage and oxidative stress increasing catabolism.<span><sup>7</sup></span> Inflammation is further potentiated by induction of apoptotic pathways, by insulin resistance and visceral obesity, leading to elevated circulating levels of proinflammatory lipid-derived molecules, and by loss of antioxidant defenses including superoxide dismutase; GSH; vitamins E, C, and A; uric acid; and thioredoxin.<span><sup>9</sup></span> In a Mendelian randomization analysis of cytokines related to sarcopenia, associations were found for IL-7, which acutely upregulates lipolysis and fat oxidation and is associated chronically with decreased muscle strength, for monocyte chemotactic protein 3, and for regulated on activation, normal T cell expressed and secreted (RANTES), which contributes to aggregation of inflammatory cells and to persistence of the inflammatory response; in addition, several cytokines were identified which appear to play protective roles but which are deficient in states of sarcopenia, including hepatocyte growth factor (HGF), which increases skeletal muscle regeneration by regulating mobilization and modification of bone marrow stem cells; interferon gamma–induced protein (IP)-10, involved in muscle regeneration; and macrophage colony-stimulating factor (M-CSF), which appears to increase muscle contractile strength.<span><sup>10</sup></span> Bone-derived cytokines (osteokines) appear to play roles similar to those of skeletal muscle–derived myokines, with mesenchymal precursor cells referred to as fibro-adipogenic progenitors (FAPs) generating adipocytes, fibroblasts, osteoblasts, and myocytes.<span><sup>11</sup></span> Abnormal FAP differentiation leads to decreased muscle regeneration in association with a dysregulated immune response, leading to persistent low-grade inflammation and excessive fat infiltration and fibrosis.<span><sup>11</sup></span> Diabetes is associated with defects in muscle regeneration with reduction in muscle stem cells and angiogenesis and increase in FAP fibrosis,<span><sup>12</sup></span> the balance shifting to adipogenesis and fibrosis in settings of inflammation, aging, oxidative stress, and insulin resistance.<span><sup>13, 14</sup></span> From this viewpoint, the combined effects of bone and muscle loss not only increase the propensity to falls and fractures but are of importance in altering the exchange of circulating factors promoting robustness versus frailty.<span><sup>15, 16</sup></span> Clinically, increased body fat with bone and muscle loss falls under the descriptive term “sarcopenic obesity.”<span><sup>17, 18</sup></span></p><p>The question has been raised as to whether intensive treatment of obesity might be detrimental in leading to reduction in lean body mass. Such effects have been seen with bariatric surgery<span><sup>19</sup></span> and with incretin-based treatments, described both semaglutide and with tirzepatide, although the proportional reduction in fat mass with these agents is considerably greater than that in lean body mass,<span><sup>20</sup></span> leading some to argue that such approaches are unlikely to cause physical frailty or sarcopenia.<span><sup>21</sup></span></p><p>Sarcopenia can be clinically assessed by measurement of handgrip strength, by using dual-energy x-ray absorptiometry (DXA) or bioelectrical impedance to measure muscle and fat mass, by simple history of activity tolerance, by ascertaining exercise capacity. An increasingly utilized approach to assessment of sarcopenia has been by taking advantage of two circulating body constituents used in estimating the glomerular filtration rate (GFR), creatinine, and cystatin C. Creatine synthesized in the liver is converted to phosphocreatine in muscle and brain, catalyzed by creatine kinase, with creatinine formed as a by-product. Cystatin C is a lysosomal proteinase inhibitor produced by all nucleated cells, present in all tissues and body fluids, and like creatinine, is cleared by glomerular filtration, with eGFR-cystatin (eGFRcys) less dependent on muscle mass than eGFR-creatinine (eGFRcr). Given this perspective, it is reasonable to consider the creatinine/cystatin C ratio (CCR) as a measure of sarcopenia. In a metanalysis of 38 reports involving 20 362 hospitalized persons, lower CCR was associated with lower gait speed, skeletal muscle mass, and handgrip strength, and with higher mortality.<span><sup>22</sup></span> Among 9894 National Health and Nutrition Examination (NHANES) 1999–2004 participants with follow-up over a mean 15.6-year period, lower CCR was associated with higher CV mortality.<span><sup>23</sup></span> In the SPRINT (Systolic Blood Pressure Intervention Trial) trial of intensive blood pressure treatment, 502 of 2571 participants aged ≥75 years met criteria for sarcopenia using CCR and gait speed data; compared with those not having sarcopenia, this group had 1.49- and 1.46-fold higher CVD event and total mortality rates, respectively.<span><sup>24</sup></span> A similar analysis of 25 825 UK Biobank participants with diabetes, without diabetic microvascular complications (DMCs) at baseline, analyzed the initial eGFRcr and eGFRcys, finding those with lower eGFRcr than eGFRcys to have higher levels of inflammatory markers and BMI as well as greater likelihood to have hypertension, cigarette use, and a history of CVD; over a 13.6-year follow-up, the development of DMCs tracked with this measure of sarcopenia.<span><sup>25</sup></span></p><p>Given this strong evidence of a relationship between sarcopenia and adverse outcome, there has been great interest in the development of measures to increase muscle regeneration, with a variety of approaches. Suggestions include various dietary approaches, including supplements with branched chain amino acids, N-3 fatty acids, vitamin D, and agents to change the gut microbiome. As an example of the latter dietary modification, in a study of 5368 participants in NHANES, those reporting higher intake of live microorganisms such as yoghurt and kimchi had 37% lower likelihood of having sarcopenia based on DXA analysis.<span><sup>26</sup></span> In addition, proposals have been made to administer hormone supplements including growth hormone, testosterone in men, and estrogen and progesterone in postmenopausal women, and pharmacologic agents including metformin, sodium-glucose counter-transport inhibitors, thiazolidinediones, glucagon-like peptide 1 receptor activators, and dipeptidyl peptidase-4 inhibitors, cell therapy approaches with myoblasts, and muscle stem cells.<span><sup>12</sup></span> Exercise training has been strongly recommended to avoid sarcopenia, and there is certainly evidence that such approaches, particularly using resistance training, reduce visceral fat, increase fat-free mass, increase strength, and reduce inflammatory cytokine levels, with reduction in triglyceride and HbA1c levels among persons with diabetes,<span><sup>27</sup></span> leading to consensus statements suggesting that exercise therapy be more widely utilized.<span><sup>28</sup></span> A randomized controlled 2 × 2 factorial trial of liraglutide 3.0 mg daily and/or a supervised exercise program showed that the combination of the two approaches led to greater weight loss and reduction in body fat<span><sup>29</sup></span>; preservation of bone mass was also greatest with combined treatment,<span><sup>30</sup></span> but the effect on muscle mass has not been reported. The evidence of benefit of all of these treatment approaches among adults with frailty has, however, been questioned, with an extensive review concluding that clinical trials of a wide variety of hormonal, exercise, and nutritional approaches have shown low to very low certainty of benefit.<span><sup>7</sup></span></p><p>We are left, then, with sarcopenia as a common clinical condition, affecting up to one-sixth of the elderly, occurring somewhat more commonly among persons with diabetes, and readily ascertainable with clinical history, with measures of strength, measures of body composition, or determination that serum creatinine levels are disproportionately low in comparison to levels of cystatin C. Sarcopenia is associated with inflammation, insulin resistance, and relative or absolute increase in fat mass. The extremely potent weight loss agents semaglutide and tirzepatide may be associated with significant reduction in lean body mass, raising the question as to whether they may over time lead to an excess of sarcopenia. Crucially, persons with sarcopenia have greater likelihood of CVD and, among those with diabetes, of neuropathy, nephropathy, and retinopathy. It therefore appears logical to conclude that therapeutic approaches to restore muscle mass and strength are needed, with the caveat that such be demonstrated to lead to improvement in outcome.</p>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.70025","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.70025","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

The term “sarcopenia” literally means “deficiency of flesh,” and is used to refer to lack of skeletal muscle. Numerous similar concepts in medicine describe the progressive loss, deficiency, atrophy, or wastage of muscle characteristic of many systemic illnesses and of aging itself. Depending on the definition used, sarcopenia affects large subsets of the population, in association with physical inactivity, cigarette smoking, and malnutrition but also paradoxically with obesity. Sarcopenia is seen with diabetes, pulmonary disease, heart disease, malignancy, and with psychiatric and neurologic illnesses including depression/anorexia and Alzheimer's and Parkinson's diseases.1 In a study carried out nearly four decades ago, total appendicular skeletal muscle mass was found to decrease in a linear fashion with age both among men and women, regardless of race or ethnic group, showing positive correlation with body weight.2 Sarcopenia can be assessed clinically with measures of strength such as the simple self-report of limitation of walking, which increases in prevalence with increasing age, to a greater extent in low- than in high-income countries, and which correlates strongly with all-cause mortality even after adjustment for age, sex, education, marital status, rural residence, and country income level, and additionally for hypertension, diabetes, coronary artery disease, stroke, body mass index (BMI), smoking, physical activity, and depression.3 In a study analyzing mortality at >12 year follow-up, those in the highest quintile of the fat-to-muscle mass ratio estimated using bioelectrical impedance among 337 951 UK Biobank participants had increased total and cardiovascular disease (CVD) mortality, both among men and women.4

Clinical conditions associated with sarcopenia overlap with features of frailty such as slowing, falls, fatigue, and weight loss, which may represent disease prodromes,5 with a continuum from robustness, with stressors leading to temporary decline in functional capacity, to pre-frailty, with only incomplete recovery from stressors, to actual frailty with failure to recover from stressors eventuating in states of dependence and disability.6 The biology of frailty involves a number of factors associated with sarcopenia, including states of dysregulated nutrient sensing, such as abnormalities of mammalian target of rapamycin (mTOR) complex 1, AMP-activated protein kinase (AMPK), and the nutrient scarcity sensors sirtuins 1 and 3, and hormonal changes associated with aging including decreased levels of the anabolic hormones dehydroepiandrosterone sulfate, testosterone, growth hormone, and insulin-like growth factor 1, and increased levels of catabolic hormones, particularly cortisol.7 Insulin can best be seen in this context as an anabolic hormone involved in nutrient storage, but rather than being deficient, it is typically present in excess in association with insulin resistance leading to reduction in its anabolic functional activity.8

Sarcopenia is associated with chronic inflammation, mediated by cellular senescence and mitochondrial dysfunction, inhibiting growth factor expression, and causing DNA damage and oxidative stress increasing catabolism.7 Inflammation is further potentiated by induction of apoptotic pathways, by insulin resistance and visceral obesity, leading to elevated circulating levels of proinflammatory lipid-derived molecules, and by loss of antioxidant defenses including superoxide dismutase; GSH; vitamins E, C, and A; uric acid; and thioredoxin.9 In a Mendelian randomization analysis of cytokines related to sarcopenia, associations were found for IL-7, which acutely upregulates lipolysis and fat oxidation and is associated chronically with decreased muscle strength, for monocyte chemotactic protein 3, and for regulated on activation, normal T cell expressed and secreted (RANTES), which contributes to aggregation of inflammatory cells and to persistence of the inflammatory response; in addition, several cytokines were identified which appear to play protective roles but which are deficient in states of sarcopenia, including hepatocyte growth factor (HGF), which increases skeletal muscle regeneration by regulating mobilization and modification of bone marrow stem cells; interferon gamma–induced protein (IP)-10, involved in muscle regeneration; and macrophage colony-stimulating factor (M-CSF), which appears to increase muscle contractile strength.10 Bone-derived cytokines (osteokines) appear to play roles similar to those of skeletal muscle–derived myokines, with mesenchymal precursor cells referred to as fibro-adipogenic progenitors (FAPs) generating adipocytes, fibroblasts, osteoblasts, and myocytes.11 Abnormal FAP differentiation leads to decreased muscle regeneration in association with a dysregulated immune response, leading to persistent low-grade inflammation and excessive fat infiltration and fibrosis.11 Diabetes is associated with defects in muscle regeneration with reduction in muscle stem cells and angiogenesis and increase in FAP fibrosis,12 the balance shifting to adipogenesis and fibrosis in settings of inflammation, aging, oxidative stress, and insulin resistance.13, 14 From this viewpoint, the combined effects of bone and muscle loss not only increase the propensity to falls and fractures but are of importance in altering the exchange of circulating factors promoting robustness versus frailty.15, 16 Clinically, increased body fat with bone and muscle loss falls under the descriptive term “sarcopenic obesity.”17, 18

The question has been raised as to whether intensive treatment of obesity might be detrimental in leading to reduction in lean body mass. Such effects have been seen with bariatric surgery19 and with incretin-based treatments, described both semaglutide and with tirzepatide, although the proportional reduction in fat mass with these agents is considerably greater than that in lean body mass,20 leading some to argue that such approaches are unlikely to cause physical frailty or sarcopenia.21

Sarcopenia can be clinically assessed by measurement of handgrip strength, by using dual-energy x-ray absorptiometry (DXA) or bioelectrical impedance to measure muscle and fat mass, by simple history of activity tolerance, by ascertaining exercise capacity. An increasingly utilized approach to assessment of sarcopenia has been by taking advantage of two circulating body constituents used in estimating the glomerular filtration rate (GFR), creatinine, and cystatin C. Creatine synthesized in the liver is converted to phosphocreatine in muscle and brain, catalyzed by creatine kinase, with creatinine formed as a by-product. Cystatin C is a lysosomal proteinase inhibitor produced by all nucleated cells, present in all tissues and body fluids, and like creatinine, is cleared by glomerular filtration, with eGFR-cystatin (eGFRcys) less dependent on muscle mass than eGFR-creatinine (eGFRcr). Given this perspective, it is reasonable to consider the creatinine/cystatin C ratio (CCR) as a measure of sarcopenia. In a metanalysis of 38 reports involving 20 362 hospitalized persons, lower CCR was associated with lower gait speed, skeletal muscle mass, and handgrip strength, and with higher mortality.22 Among 9894 National Health and Nutrition Examination (NHANES) 1999–2004 participants with follow-up over a mean 15.6-year period, lower CCR was associated with higher CV mortality.23 In the SPRINT (Systolic Blood Pressure Intervention Trial) trial of intensive blood pressure treatment, 502 of 2571 participants aged ≥75 years met criteria for sarcopenia using CCR and gait speed data; compared with those not having sarcopenia, this group had 1.49- and 1.46-fold higher CVD event and total mortality rates, respectively.24 A similar analysis of 25 825 UK Biobank participants with diabetes, without diabetic microvascular complications (DMCs) at baseline, analyzed the initial eGFRcr and eGFRcys, finding those with lower eGFRcr than eGFRcys to have higher levels of inflammatory markers and BMI as well as greater likelihood to have hypertension, cigarette use, and a history of CVD; over a 13.6-year follow-up, the development of DMCs tracked with this measure of sarcopenia.25

Given this strong evidence of a relationship between sarcopenia and adverse outcome, there has been great interest in the development of measures to increase muscle regeneration, with a variety of approaches. Suggestions include various dietary approaches, including supplements with branched chain amino acids, N-3 fatty acids, vitamin D, and agents to change the gut microbiome. As an example of the latter dietary modification, in a study of 5368 participants in NHANES, those reporting higher intake of live microorganisms such as yoghurt and kimchi had 37% lower likelihood of having sarcopenia based on DXA analysis.26 In addition, proposals have been made to administer hormone supplements including growth hormone, testosterone in men, and estrogen and progesterone in postmenopausal women, and pharmacologic agents including metformin, sodium-glucose counter-transport inhibitors, thiazolidinediones, glucagon-like peptide 1 receptor activators, and dipeptidyl peptidase-4 inhibitors, cell therapy approaches with myoblasts, and muscle stem cells.12 Exercise training has been strongly recommended to avoid sarcopenia, and there is certainly evidence that such approaches, particularly using resistance training, reduce visceral fat, increase fat-free mass, increase strength, and reduce inflammatory cytokine levels, with reduction in triglyceride and HbA1c levels among persons with diabetes,27 leading to consensus statements suggesting that exercise therapy be more widely utilized.28 A randomized controlled 2 × 2 factorial trial of liraglutide 3.0 mg daily and/or a supervised exercise program showed that the combination of the two approaches led to greater weight loss and reduction in body fat29; preservation of bone mass was also greatest with combined treatment,30 but the effect on muscle mass has not been reported. The evidence of benefit of all of these treatment approaches among adults with frailty has, however, been questioned, with an extensive review concluding that clinical trials of a wide variety of hormonal, exercise, and nutritional approaches have shown low to very low certainty of benefit.7

We are left, then, with sarcopenia as a common clinical condition, affecting up to one-sixth of the elderly, occurring somewhat more commonly among persons with diabetes, and readily ascertainable with clinical history, with measures of strength, measures of body composition, or determination that serum creatinine levels are disproportionately low in comparison to levels of cystatin C. Sarcopenia is associated with inflammation, insulin resistance, and relative or absolute increase in fat mass. The extremely potent weight loss agents semaglutide and tirzepatide may be associated with significant reduction in lean body mass, raising the question as to whether they may over time lead to an excess of sarcopenia. Crucially, persons with sarcopenia have greater likelihood of CVD and, among those with diabetes, of neuropathy, nephropathy, and retinopathy. It therefore appears logical to conclude that therapeutic approaches to restore muscle mass and strength are needed, with the caveat that such be demonstrated to lead to improvement in outcome.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Sarcopenia.
肌肉疏松症 "一词的字面意思是 "缺乏肉体",指缺乏骨骼肌。医学上有许多类似的概念,描述许多全身性疾病和衰老本身所特有的肌肉逐渐丧失、缺乏、萎缩或流失的现象。根据不同的定义,肌肉疏松症影响着大量人群,与缺乏运动、吸烟和营养不良有关,但也与肥胖有关。肌肉疏松症可见于糖尿病、肺病、心脏病、恶性肿瘤,以及精神和神经疾病,包括抑郁症/厌食症、阿尔茨海默氏症和帕金森氏症。1 近 40 年前进行的一项研究发现,不论种族或族裔,男性和女性的骨骼肌总质量随着年龄的增长呈线性下降,并与体重呈正相关。临床上可以通过测量力量来评估 "肌肉疏松症",如简单的行走受限自我报告,其患病率随着年龄的增长而增加,在低收入国家比在高收入国家患病率更高,即使在调整了年龄、性别、教育程度、婚姻状况、农村居住地和国家收入水平,以及高血压、糖尿病、冠心病、中风、体重指数(BMI)、吸烟、体力活动和抑郁等因素后,"肌肉疏松症 "仍与全因死亡率密切相关3。在一项对随访 12 年的死亡率进行分析的研究中,在 337 951 名英国生物数据库参与者中,使用生物电阻抗估算的脂肪与肌肉质量比最高的五分之一人群的总死亡率和心血管疾病(CVD)死亡率均有所上升,男性和女性均是如此。与肌肉疏松症相关的临床症状与虚弱的特征重叠,如行动迟缓、跌倒、疲劳和体重减轻,这可能是疾病的前兆,5 其中有一个连续的过程,从因压力导致功能暂时下降的健壮状态,到仅能从压力中完全恢复的虚弱前状态,再到因无法从压力中恢复而最终导致依赖和残疾状态的实际虚弱状态。虚弱的生物学原理涉及与肌肉疏松症相关的一系列因素,包括营养感应失调状态,如哺乳动物雷帕霉素靶标(mTOR)复合体 1、AMP-激活蛋白激酶(AMPK)以及营养稀缺感应器 sirtuins 1 和 3 的异常、与衰老相关的荷尔蒙变化,包括合成代谢荷尔蒙硫酸脱氢表雄酮、睾酮、生长激素和胰岛素样生长因子 1 水平的下降,以及分解代谢荷尔蒙(尤其是皮质醇)水平的上升。78 肌肉疏松症与慢性炎症有关,慢性炎症由细胞衰老和线粒体功能障碍介导,抑制生长因子的表达,造成 DNA 损伤和氧化应激,增加分解代谢。诱导细胞凋亡途径、胰岛素抵抗和内脏肥胖导致循环中促炎脂质衍生分子水平升高,以及包括超氧化物歧化酶、GSH、维生素 E、C 和 A、尿酸和硫氧还蛋白在内的抗氧化防御功能丧失,都会进一步加剧炎症。在对与肌肉疏松症有关的细胞因子进行的孟德尔随机分析中发现,IL-7、单核细胞趋化蛋白 3 和正常 T 细胞表达和分泌的活化调控因子(RANTES)与肌肉疏松症有关,前者能急性上调脂肪分解和脂肪氧化,后者则与肌肉力量下降有关;此外,还发现了几种细胞因子,它们似乎起着保护作用,但在肌肉疏松症状态下却会缺乏,包括肝细胞生长因子(HGF),它通过调节骨髓干细胞的动员和改变来增加骨骼肌的再生;γ 干扰素诱导蛋白(IP)-10,它参与肌肉再生;以及巨噬细胞集落刺激因子(M-CSF),它似乎能增加肌肉的收缩强度。10骨源性细胞因子(osteokines)的作用似乎与骨骼肌源性肌因子类似,间充质前体细胞被称为纤维-脂肪生成祖(FAPs),可生成脂肪细胞、成纤维细胞、成骨细胞和肌细胞。11 FAP 分化异常会导致肌肉再生能力下降,同时免疫反应失调,从而导致持续性低度炎症以及过度脂肪浸润和纤维化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Diabetes
Journal of Diabetes ENDOCRINOLOGY & METABOLISM-
CiteScore
6.50
自引率
2.20%
发文量
94
审稿时长
>12 weeks
期刊介绍: Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation. The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and will solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.
期刊最新文献
β-Cell gene expression stress signatures in types 1 and 2 diabetes. Association of systolic blood pressure variability with cognitive decline in type 2 diabetes: A post hoc analysis of a randomized clinical trial Sarcopenia The relationship between glucose patterns in OGTT and adverse pregnancy outcomes in twin pregnancies Gut microbiota, serum metabolites, and lipids related to blood glucose control and type 1 diabetes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1